Clinical Trial Update: Daclizumab to Treat Wegener's Granulomatosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of daclizumab for granulomatosis with polyangiitis has completed; the update notes trial status and sponsor but does not report results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatosis with Polyangiitis

Drugs mentioned

• Daclizumab (daclizumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Wegener's Granulomatosis | Phase 2 | Status: COMPLETED